KOL Insight Archives | Page 9 of 14 | Report Store

Datamonitor Healthcare Ulcerative Colitis KOL Interviews

Datamonitor Healthcare interviewed two ulcerative colitis (UC) experts, one based in Italy and the other in the US, to gauge their views on approved and late-stage pipeline drugs, treatment challenges and unmet needs and the future treatment of UC.

August 18, 2017

Find out more

Datamonitor Healthcare Systemic Lupus Erythematosus KOL Interviews

$599.00

Datamonitor Healthcare interviewed two experts on systemic lupus erythematosus (SLE) based in the US to gauge their views on currently available treatment options, pipeline drugs and challenges with clinical trial design in SLE.

August 18, 2017

Find out more

Datamonitor Healthcare Seasonal Influenza Vaccines KOL Interview – UK

$599.00

An interview with a UK key opinion leader (KOL) on seasonal influenza vaccination coverage rates and trends in main risk groups, key marketed vaccines, pipeline approaches, and the potential for a universal influenza vaccine.

November 19, 2018

Find out more

Datamonitor Healthcare Seasonal Influenza Vaccines KOL Interview – US

$599.00

An interview with a US key opinion leader (KOL) on seasonal influenza vaccination coverage rates and trends in main risk groups, key marketed vaccines, pipeline approaches, and the potential for a universal influenza vaccine

November 19, 2018

Find out more

Datamonitor Healthcare Meningococcal and Pneumococcal Vaccines KOL Interview – UK

$599.00

An interview with a UK key opinion leader (KOL) on meningococcal and pneumococcal vaccination coverage rates, vaccination rate trends in main risk groups, key marketed vaccines, pipeline approaches, and addressing unmet needs.

November 12, 2018

Find out more

Datamonitor Healthcare Meningococcal and Pneumococcal Vaccines KOL Interview – US

$599.00

An interview with a US key opinion leader (KOL) on meningococcal and pneumococcal vaccination coverage rates, vaccination rate trends in main risk groups, key marketed vaccines, pipeline approaches, and addressing unmet needs.

November 9, 2018

Find out more

Datamonitor Healthcare Type 2 Diabetes KOL Interview – UK

$599.00

In this discussion with a UK KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients.

October 12, 2018

Find out more

Datamonitor Healthcare Type 2 Diabetes KOL Interview – US

$599.00

In this discussion with a US KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients.

October 12, 2018

Find out more

Non-Small Cell Lung Cancer KOL Interview – NH, US

$1,099.00

Datamonitor Healthcare interviewed a US-based oncologist with clinical trial and commercial experience of PD-1/L1 inhibitors to gauge his views

August 30, 2018

Find out more

Key Questions in Immuno-Oncology

$1,099.00

This KOL survey answers key questions about current immunotherapy treatments and future trends in the immuno-oncology space.

August 8, 2018

Find out more

Biomedtracker Q3 2017 Outlook Report

$599.00

In this report, we cover catalysts from 21 drugs expected to occur in Q3 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

August 2, 2017

Find out more

Datamonitor Healthcare Crohn’s Disease KOL Interviews

$599.00

Datamonitor Healthcare interviewed two inflammatory bowel disease experts, one based in France and the other in Italy, to gauge their views on marketed drugs for Crohn’s disease (CD), late-stage clinical candidates, treatment challenges and unmet needs and the future treatment of CD.

April 18, 2017

Find out more

Datapack – Pharmaprojects Pharma R&D Annual Review 2017

$1,999.00

This datapack presents the supporting data behind the seminal white paper, Pharma R&D Annual Review 2017. The white paper is available for free for Biomedtracker subscribers.

April 18, 2017

Find out more

Chronic Migraine Survey

$599.00

Datamonitor conducted a 5-question survey of 26 United States and 25 European (based in France, Germany, Italy, Spain and United Kingdom) neurologists involved in pain management to gauge current prescribing practices in prophylactic treatment of chronic migraine and potential future use of the calcitonin gene-related peptide (CGRP) receptor targeting monoclonal antibody (mAb) AMG 334 (AMGN) and CGRP targeting mAbs ALD403 (ALDR) and TEV-48125 (TEVA).

March 9, 2017

Find out more

Non-Alcoholic Steatohepatitis (NASH) Survey

$599.00

Datamonitor conducted a 4-question survey of 42 United States and 40 European (based in France, Germany, Italy and United Kingdom) gastroenterologists to gauge their views on late-stage clinical candidates in non-alcoholic steatohepatitis (NASH), including Ocaliva (ICPT), elafibranor (GNFTF) and selonsertib (GILD), and their projected use of these drugs if FDA-approved.

March 9, 2017

Find out more